Pharmaceutical giant Merck & Co has agreed to pay more than US$650 million to resolve allegations of fraudulent drug pricing and improper kickbacks, the US Justice Department announced on Thursday.
The settlement hinged on two separate lawsuits relating to claims that Merck failed to pay proper rebates to government health care programs and that it made illegal payments to health care providers as inducements to use Merck products.
US Attorney General Michael Mukasey said the accord marked "one of the largest healthcare fraud settlements ever achieved by the Justice Department."
"It reflects our continuing effort to hold drug companies accountable for devising pricing schemes that deliberately seek to deny federal health care programs the same lower prices for drugs that are available to other commercial customers," Mukasey said.
The settlement was partly based on a whistleblower lawsuit brought by former Merck employee, H. Dean Steinke, who claimed that the pharmaceutical firm violated the Medicaid Rebate Statute in connection with its marketing of Zocor and Vioxx.
Zocor is a cholesterol lowering drug. Vioxx was used to treat acute pain and in the treatment of arthritis and was withdrawn from the market by Merck in September 2004.
Steinke's lawsuit alleged that Merck offered deep discounts for the two drugs if hospitals used large quantities of the drugs instead of rival treatments produced by Merck's competitors.
The Medicaid Statute requires drug manufacturers to report their "best prices" and other pricing information to the government in order to ensure that Medicaid, a government health care scheme, benefits from the same discounts and pricing enjoyed by other drug purchasers.
The government said, however, that Merck improperly did not fully reveal discounted prices it had offered to hospitals to boost its sales.
The New Jersey-based drugmaker confirmed separately that it had reached a settlement with the government and state authorities in the cases.
"The settlements do not constitute an admission by Merck of any liability or wrongdoing," Merck said in a statement.
A separate lawsuit filed by a New Orleans doctor, which also formed part of the overall settlement, alleged that Merck ran a marketing scheme which offered substantially reduced prices for its Pepcid products once hospitals agreed to use the drug.
The government will receive US$360 million under the accord while 49 states and the District of Columbia will receive more than US$290 million.
Steinke will receive more than US$64 million from the settlements under government whistleblower laws.
Merck's stock closed a scant US$0.01 lower at US$45.70 in the wake of the announcement.
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Taiwanese suppliers to Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) are expected to follow the contract chipmaker’s step to invest in the US, but their relocation may be seven to eight years away, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. When asked by opposition Chinese Nationalist Party (KMT) Legislator Niu Hsu-ting (牛煦庭) in the legislature about growing concerns that TSMC’s huge investments in the US will prompt its suppliers to follow suit, Kuo said based on the chipmaker’s current limited production volume, it is unlikely to lead its supply chain to go there for now. “Unless TSMC completes its planned six
Intel Corp has named Tasha Chuang (莊蓓瑜) to lead Intel Taiwan in a bid to reinforce relations between the company and its Taiwanese partners. The appointment of Chuang as general manager for Intel Taiwan takes effect on Thursday, the firm said in a statement yesterday. Chuang is to lead her team in Taiwan to pursue product development and sales growth in an effort to reinforce the company’s ties with its partners and clients, Intel said. Chuang was previously in charge of managing Intel’s ties with leading Taiwanese PC brand Asustek Computer Inc (華碩), which included helping Asustek strengthen its global businesses, the company
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said second-quarter revenue is expected to surpass the first quarter, which rose 30 percent year-on-year to NT$118.92 billion (US$3.71 billion). Revenue this quarter is likely to grow, as US clients have front-loaded orders ahead of US President Donald Trump’s planned tariffs on Taiwanese goods, Delta chairman Ping Cheng (鄭平) said at an earnings conference in Taipei, referring to the 90-day pause in tariff implementation Trump announced on April 9. While situations in the third and fourth quarters remain unclear, “We will not halt our long-term deployments and do not plan to
RSS